Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for diseases driven by abnormally elevated aldosterone. Their lead product candidate, lorundrostat, is a highly selective aldosterone synthase inhibitor being investigated for the treatment of hypertension. Lorundrostat has shown promising results in clinical trials, demonstrating its ability to lower blood pressure while being well-tolerated. Mineralys is headquartered in Radnor, Pennsylvania, and has a team of experienced professionals dedicated to advancing their research and development efforts.

Mineralys is committed to addressing the unmet needs of patients with hypertension and other conditions related to aldosterone dysregulation. Their innovative approach focuses on targeting the underlying cause of these conditions rather than simply managing symptoms. Mineralys has a strong track record of scientific research and is actively pursuing clinical trials to further evaluate the potential of lorundrostat for treating hypertension and other potential indications.

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted treatments for diseases driven by abnormally elevated aldosterone, particularly hypertension. The company's lead product candidate, lorundrostat, is a highly selective aldosterone synthase inhibitor that has shown promising results in clinical trials for the treatment of uncontrolled hypertension. Mineralys is committed to advancing its innovative therapies to improve the lives of patients suffering from aldosterone-driven diseases.

Mineralys Therapeutics cultivates a culture of innovation and collaboration, driven by a shared passion for developing targeted treatments for hypertension. The company values the expertise of its team members, prioritizing their commitment to the patient, and fosters an environment where individuals can contribute to a common goal.

Mineralys Therapeutics recognizes the importance of a diverse and inclusive workforce and is committed to fostering an environment where all employees feel valued and respected. The company discloses its Board Diversity Matrix, which highlights the representation of women and racial groups on the Board of Directors. While not explicitly stating specific DEI initiatives, the company's commitment to building a diverse team is evident through its efforts to attract and retain employees from various backgrounds, as well as its engagement with clinical advisory board members with a wide range of expertise in cardiovascular and renal disease.